#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease: -No flare in INEB group; 6% flare in PBO-INEB -10.9% serious infections -1 pt discontinued due to low IgG Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ